- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
India Gains 2 Adalimumab Biosimilars in 1 Week as United States, Europe Await Market Entry
Mumbai-based Glenmark Pharmaceuticals launched a biosimilar adalimumb, Adaly, in the Indian marketplace this week, following Hetero's launch of Mabura.
Mumbai-based Glenmark Pharmaceuticals launched a biosimilar adalimumb (Humira) in the Indian marketplace this week, reports The Economic Times. The drug, which will be marketed as Adaly, has launched at an undisclosed price discount to the reference product, and will be commercialized under an agreement with Cadila Healthcare.
"The launch of Adaly reaffirms our commitment toward meeting unmet needs of patients and providing the latest treatment options,” Sujesh Vasudevan of Glenmark told the Times.
News of Adaly’s launch follows close on the heels of another biosimilar adlaimumab’s Indian market entry: on January 3, drug maker Hetero launched its own biosimilar drug under the brand name Mabura. Both new biosimilars enter a marketplace in which drug maker Zydus has already launched a biosimilar adalimumab, under the brand name Exemptia, which came on the market in 2014 as the world’s first commercially available biosimilar adalimumab product.
While the Indian marketplace will now have additional, cost-saving options available, patients in other areas of the world face a longer wait for biosimilar adalimumab. In September 2017, drug maker Amgen announced that it had reached a settlement with Humira’s sponsor, AbbVie, after a lengthy patent dispute. The settlement, the terms of which were not disclosed, cleared Amgen to launch its biosimilar—Amjevita—in the United States in 2023 (despite the drug having been approved by the FDA in September 2016). Amgen fared slightly better in the European Union, where it will be allowed to introduce the drug in October of this year.
As the European and US markets await biosimilar availability, AbbVie has raised prices on the innovator Humira by 9.7% for 2018, an increase that is estimated to cost the US healthcare system an additional $1.2 billion this year alone. In 2016, Humira garnered $16.08 billion in global sales—up 14.7% from the previous year—making the reference adalimumab the top-earning drug worldwide.
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone
November 26th 2024The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
